Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
Online Programs in professional areas with the largest enrollments are evaluated annually by U.S. News, based on criteria such as employment outcomes of graduates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results